NASDAQ:ZBIO Zenas BioPharma Q2 2026 Earnings Results & Report $25.16 -1.24 (-4.70%) Closing price 04:00 PM EasternExtended Trading$25.28 +0.11 (+0.46%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zenas BioPharma missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$1.77 versus the -$1.12 consensus estimate, while revenue of $1.00 million fell short of the $15.00 million estimate by $14.00 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeBefore Market OpensConference Call7:00 AM ET Zenas BioPharma EPS ResultsActual EPS-$1.77Consensus EPS -$1.12Beat/MissMissed by -$0.65One Year Ago EPSN/AEPS Beat Rate2 of last 6 quartersZenas BioPharma Revenue ResultsActual Revenue$1.00 millionExpected Revenue$15.00 millionBeat/MissMissed by -$14.00 millionYoY Revenue GrowthN/AUpcoming EarningsZenas BioPharma's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zenas BioPharma Q2 2026 Earnings FAQ Did Zenas BioPharma beat earnings estimates for Q2 2026? Zenas BioPharma (NASDAQ:ZBIO) reported earnings of -$1.77 per share for Q2 2026, missing the consensus estimate of -$1.12. The report was announced on Thursday, August 13, 2026. What was Zenas BioPharma's revenue for Q2 2026? Zenas BioPharma reported revenue of $1.00 million for Q2 2026, against a consensus estimate of $15.00 million. When is Zenas BioPharma's next earnings date? Zenas BioPharma's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zenas BioPharma on the company's earnings history page. Zenas BioPharma Earnings HeadlinesZenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data ReleaseOctober 13 at 7:29 AM | uk.finance.yahoo.comZenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related DiseaseOctober 12 at 7:45 AM | markets.businessinsider.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 13 at 1:00 AM | Stansberry Research (Ad)Head-To-Head Review: MacroGenics (NASDAQ:MGNX) vs. Zenas BioPharma (NASDAQ:ZBIO)October 12 at 5:14 AM | americanbankingnews.comZenas BioPharma, Inc. (ZBIO) - What Are Researchers Saying About This Stock?October 12 at 2:15 AM | americanbankingnews.comZenas Biopharma Inc (ZBIO)October 10 at 3:31 AM | investing.comSee More Zenas BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email. Email Address About Zenas BioPharmaZenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments. Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells. The company is evaluating the therapy in immune-mediated diseases, including IgG4-related disease and systemic lupus erythematosus. Zenas BioPharma was established to advance therapies for autoimmune and other immune-mediated conditions and conducts clinical development activities through studies involving patients in multiple geographic regions. The company is headquartered in Waltham, Massachusetts, and its shares began trading on the Nasdaq under the symbol ZBIO in 2024.View Zenas BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
